Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Published:2016-11 Issue:11 Volume:11 Page:1962-1969
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Li Yang-Si,Jiang Ben-Yuan,Yang Jin-Ji,Tu Hai-Yan,Zhou Qing,Guo Wei-Bang,Yan Hong-Hong,Wu Yi-Long

Funder

National Health and Family Planning Commission

Lung Cancer Translational Medicine

Guangzhou Science and Technology Bureau

Natural Science Foundation of Guangdong Province

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference41 articles.

1. Neoplastic meningitis;Chamberlain;J Clin Oncol,2005

2. Neoplastic meningitis;Gleissner;Lancet Neurol,2006

3. Epidermal growth factor receptor tyrosine kinase inhibitors for non–small-cell lung cancer patients with leptomeningeal carcinomatosis;Liao;J Thorac Oncol,2015

4. Management of leptomeningeal metastases: prognostic factors and associated outcomes;Brower;J Clin Neurosci,2016

5. Carcinomatous meningitis: leptomeningeal metastases in solid tumors;Le Rhun;Surg Neurol Int,2013

Cited by 221 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of Cytologic Findings and Circulating Tumor DNA From Cerebrospinal Fluid Revealed SCLC Transformation in Patients With Leptomeningeal Metastases of Lung Adenocarcinoma;JTO Clinical and Research Reports;2024-09

2. Treatment Advances in Lung Cancer with Leptomeningeal Metastasis;Current Cancer Drug Targets;2024-09

3. Tyrosine kinase inhibitors in the treatment of leptomeningeal carcinomatosis;Cell Biology International;2024-08-13

4. Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM);Journal of Clinical Oncology;2024-08-10

5. Leptomeningeal Metastasis in the Era of CNS-Penetrant Tyrosine Kinase Inhibitor Therapy;Journal of Clinical Oncology;2024-08-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3